Add BrightSurf on Google Email

Real world data shows impact of immunotherapy in populations underrepresented in clinical trials, according to JNCCN study

A recent study published in JNCCN found that patients from underrepresented groups treated with first-line immunotherapy for advanced Non-Small Cell Lung Cancer (NSCLC) showed similar survival outcomes as their White counterparts. The study analyzed data from 248 patients and highlighted the need for more diverse patient representation...

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·DateDec 11, 2023

'Exceptional' results in phase III leukaemia trial

A phase III trial has found that personalised treatment for chronic lymphocytic leukaemia (CLL) can improve survival and remission rates. The trial showed that individualising therapy based on regular blood tests significantly improved progression-free and overall survival in patients with previously untreated CLL.

SourceUniversity of Leeds·JournalNew England Journal of Medicine·DateDec 10, 2023

Long-term results show combination treatment that skips chemotherapy is effective for older patients with Ph+ ALL

The study found that dasatinib and blinatumomab combination treatment resulted in excellent median overall survival and disease-free survival times for patients 65 and older with Philadelphia chromosome-positive acute lymphoblastic leukemia. The regimen confirmed benefits of this treatment are durable, with a median overall survival of...

SourceSWOG Cancer Research Network·TypeRandomized controlled/clinical trial·DateDec 9, 2023

First-in-human clinical trial of CAR T cell therapy with new binding mechanism shows promising early responses

A Phase I clinical trial of AT101, a new CAR T cell therapy targeting CD19 through a distinct binding mechanism, has shown a 100% complete response rate in patients with relapsed or refractory B cell non-Hodgkin's lymphoma. The treatment was found to be safe with manageable side effects and is expected to build upon the effectiveness o...

“On-demand” HIV prevention method for women being tested in second early phase trial

The TAF/EVG fast-dissolving vaginal insert is being evaluated in a Phase 1 study to determine its safety and user acceptability. The study aims to assess the product's effectiveness as an on-demand HIV prevention method for women, particularly those who do not want or can't use daily PrEP or long-acting products.

Can brain stimulation benefit individuals with schizophrenia?

Researchers found that repetitive transcranial magnetic stimulation (rTMS) improved event-based prospective memory in patients with schizophrenia, but not time-based prospective memory. The study suggests rTMS as a potential therapeutic option for prospective memory impairments in individuals with schizophrenia.

SourceWiley·JournalNeuropsychopharmacology Reports·DateDec 6, 2023

Experimental HIV vaccine regimens likely to be ineffective in preventing HIV acquisition, PrEPVacc study reports

A new HIV prevention study, PrEPVacc, has stopped further vaccinations due to little or no chance of demonstrating vaccine efficacy in preventing HIV acquisition. The trial, testing two different combinations of HIV vaccines and a new oral PrEP drug formulation, aims to find out if either can prevent HIV infection.

SourcePrEPVacc·TypeRandomized controlled/clinical trial·DateDec 6, 2023

Endovascular catheter opens blocked arteries deep within lungs, researchers at the Lewis Katz School of Medicine at Temple University report

Researchers at Temple University Health System report that the BASHIR Endovascular Catheter reduces blockages in lung arteries and correlates with improved right ventricle function, suggesting better survival outcomes. The catheter also shows significantly lower bleeding rates compared to other devices.

SourceTemple University Health System·JournalJACC Advances·DateDec 4, 2023

Ten years on, Lung-MAP success demonstrates potential of public-private partnerships in clinical research

The Lung-MAP trial has demonstrated the potential of public-private partnerships in clinical research, increasing access to new treatment options for patients with lung cancer. The unique partnership between academia, advocacy, federal agencies, and industry has led to a more representative patient group being enrolled in clinical trials.

SourceSWOG Cancer Research Network·JournalClinical Cancer Research·TypeCommentary/editorial·DateDec 1, 2023

More than $13M awarded to study childhood obesity interventions in rural and minority communities in Louisiana and Tennessee

Researchers aim to determine optimal duration and intensity of behavioral interventions for childhood obesity among rural and minority children. The five-year study, funded by the Patient-Centered Outcomes Research Institute, will enroll 900 parent-child pairs and compare different 'dosing' combinations of face-to-face intervention time.

New drug developed for melanoma and lung cancer shows potential in treatment of cutaneous squamous cell carcinoma – the most common metastatic skin cancer

A new study at the University of Turku discovered that plixorafenib inhibits multiple signaling pathways in cutaneous squamous cell carcinoma, showing promise for treatment. The drug was originally developed for melanoma and lung cancer, but its effectiveness against cSCC is significant.

SourceUniversity of Turku·JournalOncogene·DateNov 22, 2023

Immunotherapy drug is well tolerated in lung cancer patients with limited physical function, study suggests

A phase 2 trial found that durvalumab is safe and may benefit overall survival in non-small cell lung cancer patients with borderline performance status. The study also showed stable quality of life and a lower incidence of severe treatment-related adverse events compared to platinum doublet chemotherapy.

SourceUniversity of Pittsburgh·JournalEClinicalMedicine·TypeRandomized controlled/clinical trial·DateNov 21, 2023

Breakthrough in bladder cancer research

Two phase-3 clinical trials demonstrate a significant increase in overall survival and progression-free survival for bladder cancer patients treated with immunotherapy combinations. The studies show a 22% reduction in the risk of death compared to chemotherapy alone, providing a promising new approach for treating advanced bladder cancer.

SourceNetherlands Cancer Institute·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateNov 16, 2023

Association of molecular subtypes in bladder cancer with response to neoadjuvant chemotherapy, progression, and survival

Researchers found a modest improvement in predicting pathologic response to chemotherapy using molecular subtypes, but no association with overall survival and progression-free survival. The study suggests the need for subtype-directed therapy trials to test targeted treatments.

SourceSWOG Cancer Research Network·JournalClinical Cancer Research·TypeRandomized controlled/clinical trial·DateNov 15, 2023

Decline in estimated glomerular filtration rate after dapagliflozin in heart failure with mildly reduced or preserved ejection fraction

Patients with heart failure treated with dapagliflozin experienced frequent initial estimated glomerular filtration rate declines, but without increased cardiovascular or kidney event risks. The study suggests that sodium-glucose cotransporter-2 inhibitors can be safely continued in patients experiencing eGFR decline.

SourceJAMA Network·JournalJAMA Cardiology·DateNov 12, 2023

A comparative analysis of two SARS-CoV-2 vaccines: Insights from Korea University College of Medicine

A recent study published in eClinical Medicine found that the GB510/AS03 vaccine elicited a stronger antibody immune response against the ancestral SARS-CoV-2 strain compared to ChAdOx1-S. The vaccine demonstrated robust safety and efficacy, with no significant safety concerns identified.

SourceKorea University College of Medicine·JournalEClinicalMedicine·TypeRandomized controlled/clinical trial·DateNov 8, 2023

U of M Medical School research team finds novel drug improves outcomes for patients with rare kidney disorder

Researchers discovered that patients with FSGS who received sparsentan treatment experienced improved kidney function and reduced proteinuria, a key indicator of kidney damage. The study suggests sparsentan may be a potential new treatment option for the disorder, offering hope for patients affected by FSGS.

SourceUniversity of Minnesota Medical School·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateNov 3, 2023

Urine biomarkers can outperform serum biomarkers in certain diseases

Researchers found that urine biomarkers can be more accurate than serum biomarkers for detecting specific diseases. The study highlights the potential of combining urinary and serum biomarkers for holistic disease diagnosis and management. However, challenges remain in standardizing urinary biomarker assays and expanding their applicat...

SourceKeAi Communications Co., Ltd.·JournalURINE·TypeLiterature review·DateNov 1, 2023

RCSI study shows survival benefit of augmentation therapy for people with the genetic lung condition AATD

A new study by RCSI University of Medicine and Health Sciences found that boosting levels of a deficient protein improves survival rates for people with severe alpha-1 antitrypsin deficiency. The research, which tracked health data from over 600 patients, showed a clear survival benefit from augmentation therapy.

SourceRCSI·JournalAmerican Journal of Respiratory and Critical Care Medicine·DateNov 1, 2023

Sigh ventilation in patients with trauma

A randomized clinical trial of 524 trauma patients found that adding sigh breaths to mechanical ventilation did not increase ventilator-free days. However, prespecified secondary data suggest that sighs are well-tolerated and may improve clinical outcomes in this patient population.

SourceJAMA Network·JournalJAMA·DateOct 25, 2023

Brain-computer interface restores control of home devices for Johns Hopkins patient with ALS

A brain-computer interface (BCI) has been successfully used to restore control of home devices for a patient with ALS, allowing the individual to navigate a communication board and smart devices without recalibration. The BCI device was implanted on the surface of the brain areas responsible for speech and upper limb function, enabling...

SourceJohns Hopkins Medicine·JournalAdvanced Science·DateOct 25, 2023